Star Sports Medicine

Star Sports Medicine (Ticker: 1609 HK) provides clinical sports medicine solutions, including products for treating soft-tissue injuries affecting the rotator cuff, ligaments and meniscus. The profile reports an approximate 6.5% share of China’s sports medicine implants and instruments market. Planned uses of IPO proceeds include research and development, expanding product capacity, brand promotion, business development, working capital and strategic acquisitions. The offering is structured as an H Share listing.

The scheduled listing date on Hong Kong Stock Exchange was May 5, 2026. The proposed offering comprises 8,420,000 shares at an indicative price of HKD 98.50 per share. The base offering would represent HKD 829.37 million, approximately $105.68 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is $689.37 million.

CCB International Capital and CITIC Securities are joint sponsors. CLSA, CMBC Securities and China Galaxy International are joint managers.